Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.
复制标题
DOI:
10.1093/ckj/sfx081
复制
发表时间:
2017-10
影响因子:
4.6
通讯作者:
Kavanagh D
中科院分区:
文献类型:
--
作者:
Brocklebank V;Kavanagh D
Thrombotic microangiopathy (TMA), characterized by organ injury occurring consequent to severe endothelial damage, can manifest in a diverse range of diseases. In complement-mediated atypical haemolytic uraemic syndrome (aHUS) a primary defect in complement, such as a mutation or autoantibody leading to over activation of the alternative pathway, predisposes to the development of disease, usually following exposure to an environmental trigger. The elucidation of the pathogenesis of aHUS resulted in the successful introduction of the complement inhibitor eculizumab into clinical practice. In other TMAs, although complement activation may be seen, its role in the pathogenesis remains to be confirmed by an interventional trial. Although many case reports in TMAs other than complement-mediated aHUS hint at efficacy, publication bias, concurrent therapies and in some cases the self-limiting nature of disease make broader interpretation difficult. In this article, we will review the evidence for the role of complement inhibition in complement-mediated aHUS and other TMAs.
登录
查看更多内容
DOI:
10.1111/j.1600-0897.2009.00731.x
发表时间:
2009-10-01
影响因子:
3.6
作者:
Ari, Elif;Yilmaz, Yusuf;Ozener, Cetin
通讯作者:
Ozener, Cetin
影响因子:
6.1
作者:
Ahlenstiel-Grunow, Thurid;Hachmeister, Svenja;Pape, Lars
通讯作者:
Pape, Lars
影响因子:
11.8
作者:
Becker, S;Fusco, G;Feinberg, J
通讯作者:
Feinberg, J
影响因子:
3.4
作者:
Bermea, Rene S.;Sharma, Niharika;Liarski, Vladimir M.
通讯作者:
Liarski, Vladimir M.
影响因子:
4.4
作者:
Blanc, Caroline;Togarsimalemath, Shambhuprasad Kotresh;Dragon-Durey, Marie-Agnes
通讯作者:
Dragon-Durey, Marie-Agnes